XTX Topco Ltd Acquires 3,811 Shares of Quest Diagnostics Incorporated (NYSE:DGX)

XTX Topco Ltd grew its position in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 127.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,791 shares of the medical research company's stock after acquiring an additional 3,811 shares during the period. XTX Topco Ltd's holdings in Quest Diagnostics were worth $930,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Rothschild Investment LLC acquired a new stake in shares of Quest Diagnostics in the second quarter valued at approximately $26,000. Spartan Planning & Wealth Management acquired a new stake in Quest Diagnostics during the 4th quarter worth $31,000. Innealta Capital LLC acquired a new stake in Quest Diagnostics during the 2nd quarter worth $31,000. Larson Financial Group LLC grew its holdings in Quest Diagnostics by 77.5% during the 2nd quarter. Larson Financial Group LLC now owns 229 shares of the medical research company's stock worth $31,000 after acquiring an additional 100 shares during the period. Finally, Riverview Trust Co acquired a new stake in Quest Diagnostics during the 1st quarter worth $33,000. Institutional investors own 88.06% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on DGX shares. JPMorgan Chase & Co. lifted their target price on shares of Quest Diagnostics from $152.00 to $155.00 and gave the stock a "neutral" rating in a report on Thursday, May 30th. Robert W. Baird boosted their price target on shares of Quest Diagnostics from $153.00 to $154.00 and gave the company a "neutral" rating in a report on Wednesday, July 24th. Evercore ISI assumed coverage on shares of Quest Diagnostics in a report on Wednesday, August 28th. They issued an "in-line" rating and a $165.00 price target for the company. StockNews.com raised shares of Quest Diagnostics from a "hold" rating to a "buy" rating in a report on Tuesday, July 23rd. Finally, Citigroup raised shares of Quest Diagnostics from a "neutral" rating to a "buy" rating and boosted their price target for the company from $145.00 to $165.00 in a report on Wednesday, July 10th. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Quest Diagnostics currently has an average rating of "Hold" and a consensus price target of $154.33.

Quest Diagnostics Stock Performance

Shares of DGX stock traded down $2.13 on Friday, reaching $152.99. The stock had a trading volume of 1,456,258 shares, compared to its average volume of 944,780. The company has a quick ratio of 0.91, a current ratio of 1.00 and a debt-to-equity ratio of 0.57. The firm's 50-day moving average is $150.61 and its two-hundred day moving average is $141.09. The firm has a market capitalization of $17.00 billion, a price-to-earnings ratio of 20.59, a P/E/G ratio of 2.80 and a beta of 0.89. Quest Diagnostics Incorporated has a 12 month low of $119.59 and a 12 month high of $159.36.

Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $2.35 EPS for the quarter, beating analysts' consensus estimates of $2.31 by $0.04. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.39 billion. During the same quarter in the prior year, the business earned $2.30 EPS. Quest Diagnostics's quarterly revenue was up 2.5% on a year-over-year basis. On average, research analysts expect that Quest Diagnostics Incorporated will post 8.89 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 21st. Shareholders of record on Friday, October 4th will be given a dividend of $0.75 per share. The ex-dividend date is Friday, October 4th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.96%. Quest Diagnostics's payout ratio is presently 40.38%.

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Mark E. Delaney sold 420 shares of the stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total transaction of $60,093.60. Following the transaction, the senior vice president now owns 5,019 shares in the company, valued at approximately $718,118.52. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, SVP Karthik Kuppusamy sold 1,990 shares of the company's stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total transaction of $304,987.40. Following the completion of the sale, the senior vice president now owns 11,459 shares of the company's stock, valued at approximately $1,756,206.34. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Mark E. Delaney sold 420 shares of the company's stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $143.08, for a total transaction of $60,093.60. Following the sale, the senior vice president now directly owns 5,019 shares of the company's stock, valued at approximately $718,118.52. The disclosure for this sale can be found here. Company insiders own 0.79% of the company's stock.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.